Advancements in Metabolomics Research in Benign Gallbladder Diseases: A Review

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2024 May 24

PMID 38788004

Authors

Yanzhang Du

Wennie A Wijaya

Wei Hui Liu

Affiliations

Soon will be listed here.

Abstract

The burgeoning field of metabolomics has piqued the interest of researchers in the context of benign gallbladder diseases, which include conditions such as gallbladder polyps, gallstones, and cholecystitis, which are common digestive system disorders. As metabolomics continues to advance, researchers have increasingly focused their attention on its applicability in the study of benign gallbladder diseases to provide new perspectives for diagnostic, therapeutic, and prognostic evaluation. This comprehensive review primarily describes the techniques of liquid chromatography-mass spectrometry, gas chromatography-mass spectrometry, and nuclear magnetic resonance and their respective applications in the study of benign gallbladder disease. Metabolomics has made remarkable progress in various aspects of these diseases, ranging from early diagnosis, etiological research, assessment of disease progression and prognosis, and optimization of therapeutic strategies. However, challenges remain in the field of metabolomics in the study of benign gallbladder diseases. These include issues related to data processing and analysis, biomarker discovery and validation, interdisciplinary research integration, and the advancement of personalized medicine. This article attempts to summarize research findings to date, highlight future research directions, and provide a reference point for metabolomics research in benign gallbladder disease.

References

Putri S, Yamamoto S, Tsugawa H, Fukusaki E . Current metabolomics: technological advances. J Biosci Bioeng. 2013; 116(1):9-16. DOI: 10.1016/j.jbiosc.2013.01.004. View

Klupczynska A, Derezinski P, Kokot Z . METABOLOMICS IN MEDICAL SCIENCES--TRENDS, CHALLENGES AND PERSPECTIVES. Acta Pol Pharm. 2015; 72(4):629-41. View

Zhang A, Sun H, Yan G, Wang P, Han Y, Wang X . Metabolomics in diagnosis and biomarker discovery of colorectal cancer. Cancer Lett. 2013; 345(1):17-20. DOI: 10.1016/j.canlet.2013.11.011. View

Peng J, Chen Y, Chen C, Li L . Development of a universal metabolome-standard method for long-term LC-MS metabolome profiling and its application for bladder cancer urine-metabolite-biomarker discovery. Anal Chem. 2014; 86(13):6540-7. DOI: 10.1021/ac5011684. View

Trygg J, Holmes E, Lundstedt T . Chemometrics in metabonomics. J Proteome Res. 2007; 6(2):469-79. DOI: 10.1021/pr060594q. View

Beale D, Pinu F, Kouremenos K, Poojary M, Narayana V, Boughton B . Review of recent developments in GC-MS approaches to metabolomics-based research. Metabolomics. 2019; 14(11):152. DOI: 10.1007/s11306-018-1449-2. View

Yang S, Ding J, Zheng J, Hu B, Li J, Chen H . Detection of melamine in milk products by surface desorption atmospheric pressure chemical ionization mass spectrometry. Anal Chem. 2009; 81(7):2426-36. DOI: 10.1021/ac900063u. View

Mohammad Alizadeh A . Cholangitis: Diagnosis, Treatment and Prognosis. J Clin Transl Hepatol. 2017; 5(4):404-413. PMC: 5719198. DOI: 10.14218/JCTH.2017.00028. View

Hao Z, Tao K, Wu K, Luo Y, Lu Y, Li B . Alterations of gut microbiome and metabolite profiles in choledocholithiasis concurrent with cholangitis. Hepatol Int. 2021; 16(2):447-462. DOI: 10.1007/s12072-021-10231-5. View

10.

Kanani H, Chrysanthopoulos P, Klapa M . Standardizing GC-MS metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 871(2):191-201. DOI: 10.1016/j.jchromb.2008.04.049. View

11.

Wishart D . Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 2016; 15(7):473-84. DOI: 10.1038/nrd.2016.32. View

12.

Chen C, Lu C, Chang F, Lee S . Risk factors for gallbladder polyps in the Chinese population. Am J Gastroenterol. 1997; 92(11):2066-8. View

13.

Wang H, Liu J, Cooks R, Ouyang Z . Paper spray for direct analysis of complex mixtures using mass spectrometry. Angew Chem Int Ed Engl. 2010; 49(5):877-80. DOI: 10.1002/anie.200906314. View

14.

Yu M, Kim Y, Park H, Jung S . Benign gallbladder diseases: Imaging techniques and tips for differentiating with malignant gallbladder diseases. World J Gastroenterol. 2020; 26(22):2967-2986. PMC: 7304100. DOI: 10.3748/wjg.v26.i22.2967. View

15.

Boulesteix A, Strimmer K . Partial least squares: a versatile tool for the analysis of high-dimensional genomic data. Brief Bioinform. 2006; 8(1):32-44. DOI: 10.1093/bib/bbl016. View

16.

Kimura Y, Takada T, Kawarada Y, Nimura Y, Hirata K, Sekimoto M . Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg. 2007; 14(1):15-26. PMC: 2784509. DOI: 10.1007/s00534-006-1152-y. View

17.

Want E, Wilson I, Gika H, Theodoridis G, Plumb R, Shockcor J . Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc. 2010; 5(6):1005-18. DOI: 10.1038/nprot.2010.50. View

18.

Hood L, Friend S . Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol. 2011; 8(3):184-7. DOI: 10.1038/nrclinonc.2010.227. View

19.

Oh S, Han H, Kim H . Comet tail artifact on ultrasonography: is it a reliable finding of benign gallbladder diseases?. Ultrasonography. 2018; 38(3):221-230. PMC: 6595125. DOI: 10.14366/usg.18029. View

20.

Hundal R, Shaffer E . Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014; 6:99-109. PMC: 3952897. DOI: 10.2147/CLEP.S37357. View